“We will be the world’s best at what is important to our Customers in Infection Control”
Kersia, at the forefront of the fight against Coronavirus worldwide.
Trusted in Infection Control since 1984
Investing heavily in research and development, with a newly opened state of the art microbiology laboratory, we are committed to driving a significant positive health impact globally by reducing surface contamination and improving access to safe drinking water.
Our effervescent disinfection tablets are the only product approved to kill the pathogens in surface biofilm, achieving a 7 log reduction in 4 minutes. 99% of all pathogens live on surfaces in a biofilm.
Our NaDCC effervescent range of tablets are currently used in the top 5 US hospitals.
US EPA registered; they have demonstrated effectiveness against similar viruses to Wuhan coronavirus on hard, non-porous surfaces. Therefore, when used in accordance with directions, our NaDCC tablets are effective against SARS-Cov-2
Products:
US Klorsept: US EPA Reg No: 71847-6
Klorkleen 2: US EPA Reg No: 71847-7
USA Contact: Dan Mueller
E-mail: dan.mueller@kersia-group.com
M: +1 206 741 5981
Dan Mueller
Senior Vice President
Dan Mueller
Dan Mueller is the Senior Vice President, North American Sales for Kersia Medical. Steeped in the Infection Prevention Healthcare sector, Dan brings a deep-rooted passion for problem solving and 25+ years of experience delivering superior pipeline development, market expansion and revenue-maximizing solutions in the U.S. and global markets.
Dan holds a Bachelor of Science in Marketing, from Miami University and a Master of Arts in Organizational Leadership from Gonzaga University. Dan resides with his family in Seattle and is an outdoor and triathlon enthusiast. His volunteering work includes The Multiple Sclerosis Bike 150, National MS Society Team Leader and The Multiple Myeloma Research Foundation.
